In vitro induction of apoptosis in U937 cells by perillyl alcohol with sensitization by pentoxifylline: Increased BCL-2 and BAX protein expression

Chemotherapy

Volumn 52, Issue 6, 2006, Pages 308-315

  Gomez Contreras P C ^a   Hernandez Flores G ^a   Ortiz Lazareno, P C ^a   Del Toro Arreola, S ^b   Delgado Rizo, V ^b   Lerma Diaz J M ^a   Barba Barajas, M ^a   Dominguez Rodriguez J R ^a   Cuellar, A Bravo ^a,b,c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA DE OCCIDENTE   (Mexico)

Author keywords

Apoptosis; Bax; Bcl 2; Pentoxifylline; Perillyl alcohol

Indexed keywords

CARBOCYANINE; DIHEXYLOXACARBOCYANINE IODIDE; PENTOXIFYLLINE; PERILLYL ALCOHOL; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN U937; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MYELOMONOCYTIC LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID; MEMBRANE POTENTIAL, MITOCHONDRIAL; MONOTERPENES; PENTOXIFYLLINE; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; U937 CELLS;

EID: 33750240101     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096003     Document Type: Article

References (41)

1. Greenwald P: Cancer chemoprevention. Science, medicine and the future. BMJ 2002;324:714-718.
2. Greenwald P: Cancer prevention clinical trials. J Clin Oncol 2002;20:14S-22S.
3. Belanger JT: Perillyl alcohol: applications in oncology. Altern Med Rev 1998;3:448-457.
4. Wagner KH, Elmadfa I: Biological relevance of terpenoids. Overview focusing on mono-, di-and tetraterpenes (review). Ann Nutr Metab 2003;47:95-106.
5. Lluria-Prevatt M, Morreale J, Gregus J, et al: Effects of perillyl alcohol on melanoma in the TPras mouse model. Cancer Epidemiol Biomarkers Prev 2002;11:573-579.
6. Morse MA, Stoner GD: Cancer chemoprevention: principles and prospects. Carcinogenesis 1993;14:1737-1746.
7. Clark SS, Perman SM, Sahin MB, Jenkins GJ, Elegbede JA: Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest. Leukemia 2002;16:213-222.
8. Crowell PL: Prevention and therapy of cancer by dietary monoterpenes. J Nutr 1999;129:775S-778S.
9. Hohl RJ, Lewis K: Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 1995;270:17508-17512.
10. Stayrook KR, McKinzie JH, Barbhaiya LH, Crowell PL: Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells. Anticancer Res 1998;18:823-828.
11. Malumbres M, Pellicer A: RAS pathways to cell cycle control and cell transformation. Front Biosci 1998;3:d887-d912.
12. Berchtold CM, Chen KS, Miyamoto S, Gould MN: Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-κB pathway. Cancer Res 2005;65:8558-8566.
13. Shi W, Gould MN: Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol. Carcinogenesis 2002;23:131-142.
14. Jukna JJ, Nicholson CD: The effect of denbufylline on the viscosity of rat whole blood and on the deformability (filterability) of rat blood cell suspensions. Naunyn Schmiedebergs Arch Pharmacol 1987;335:445-448.
15. Sibtain A, Hill S, Goodchild K, Shah N, Saunders M, Hoskin PJ: The modification of human tumor flow using pentoxifylline, nicotinamide and carbogen. Radiother Oncol 2002;62:69-76.
16. 2+-induced potassium efflux and on the ATPase-activity of erythrocytes (author's transl. from German). Arzneimittelforschung 1981;31:825-828.
17. Essayan D: Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001;108:671-680.
18. Ohsaki Y, Ishida S, Fujikane T, Kikuchi K: Pentoxifylline potentiates the antitumor effect of cisplatin and etoposide on human lung cancer cell lines. Oncology 1996;53:327-333.
19. Alas S, Bonavida B, Emmanouilides C: Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 2000;20:2961-2966.
20. Zywietz F, Bohm L, Sagowski C, Kehrl W: Pentoxifylline enhances tumor oxygenation and radiosensitivity in rat rhabdomyosarcomas during continuous hyperfractionated irradiation. Strahlenther Onkol 2004;180:306-314.
21. Futakuchi M, Ogawa K, Tamano S, Takahashi S, Shirai T: Suppression of metastasis by nuclear factor κB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. Cancer Sci 2004;95:18-24.
22. Gude RP, Binda MM, Presas HL, Klein-Szanto AJ, Bonfil RD: Studies on the mechanisms responsible for inhibition of experimental metastasis of B16-F10 murine melanoma by pentoxifylline. J Biomed Sci 1999;6:133-141.
23. Lazarczyk M, Grzela T, Niderla J, et al: Pentoxifylline inhibits leukocyte infiltration and splenocyte cytotoxicity against murine colon adenocarcinoma. Oncol Rep 2003;10:839-843.
24. Houston DS: Tissue factor - a therapeutic target for thrombotic disorders. Expert Opin Ther Targets 2002;6:159-174.
25. Wang MH, Wang D, Chen YQ: Oncogenic and invasive potentials of human macrophagestimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 2003;24:1291-1300.
26. Rube CE, Wilfert F, Uthe D, et al: Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. Radiother Oncol 2002;64:177-187.
27. Chen JJ, Yao PL, Yuan A, et al: Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003;9:729-737.
28. Gajkowska B, Wojewodzka U, Gajda J: Translocation of Bax and Bid to mitochondria, endoplasmic reticulum and nuclear envelope: possible control points in apoptosis. J Mol Histol 2004;35:11-19.
29. Smaili SS, Hsu YT, Carvalho AC, Rosenstock TR, Sharpe JC, Youle RJ: Mitochondria, calcium and pro-apoptotic proteins as mediators in cell death signaling. Braz J Med Biol Res 2003;36:183-190.
30. Dominguez-Rodriguez JR, Chaparro-Huerta V, Hernandez-Flores G, et al: In vivo adriamycin-induced apoptosis in peritoneal murine macrophages: partial participation of a caspase cascade. Anticancer Res 2004;24:2689-2696.
31. Ohsaki VIS, Fujikane T, Kikuchi K: Pentoxifylline potentiates the antitumor effect of cisplatin and etoposide on human lung cancer cell lines. Lung Cancer 1997;16:278.
32. Andela VB, Gingold BI, Souza MD, et al: Clinical relevance of increased retinoid and cAMP transcriptional programs in tumor cells rendered non-malignant by dominant negative inhibition of NKκB. Cancer Lett 2003;194:37-43.
33. Pulfer M, Murphy RC: Electrospray mass spectrometry of phospholipids. Mass Spectrom Rev 2003;22:332-364.
34. Willems GM, Janssen MP, Comfurius P, Galli M, Zwaal RF, Bevers EM: Competition of annexin V and anticardiolipin antibodies for binding to phosphatidylserine containing membranes. Biochemistry 2000;39:1982-1989.
35. Qi L, Danielson ND, Dai Q, Lee RM: Capillary electrophoresis of cardiolipin with on-line dye interaction and spectrophotometric detection. Electrophoresis 2003;24:1680-1686.
36. Iverson SL, Enoksson M, Gogvadze V, Ott M, Orrenius S: Cardiolipin isnot required for Bax-mediated cytochrome c release from yeast mitochondria. J Biol Chem 2004;279:1100-1107.
37. Thees S, Hubbard GB, Winckler J, Schultz C, Rami A: Specific alteration of the Bax/Bcl2 ratio and cytochrome c without execution of apoptosis in the hippocampus of aged baboons. Restor Neurol Neurosci 2005;23:1-9.
38. Ascensao AA, Magalhaes J, Soares JM, et al: Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis. Am J Physiol Heart Circ Physiol 2005;289:H722-H731.
39. Meckey TJBA, Amin P, Jacobs SC, Kyprianou N: bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 1998;52:1085-1090.
40. Ulukaya E, Colakogullari M, Wood EJ: Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay. Chemotherapy 2004;50:43-50.
41. Ramos MG, Rabelo FL, Brumatti G, Bueno-da-Silva AE, Amarante-Mendes GP, Alvarez-Leite JI: Butyrate increases apoptosis induced by different antineoplastic drugs in monocytic leukemia cells. Chemotherapy 2004;50:221-228.